Adicet Bio Q4 2025 Earnings Report

Adicet Bio EPS Results

• Actual EPS: -$2.94
• Consensus EPS: -$3.23
• Beat/Miss: Beat by +$0.29
• One Year Ago EPS: N/A

Adicet Bio Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Adicet Bio Announcement Details

• Quarter: Q4 2025
• Date: 3/12/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Adicet Bio (NASDAQ:ACET) (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies. The company also has a pipeline of next-generation candidates targeting solid tumors and autoimmune indications, each built on its platform’s ability to combine γδ T cell receptors with co-stimulatory and cytokine support elements. Early‐stage clinical studies are under way to evaluate safety, tolerability, and preliminary efficacy in multiple patient populations.

Founded in 2016 and headquartered in South San Francisco, California, Adicet Bio maintains operations in both the U.S. and Suzhou, China, where it conducts process development and manufacturing. The company completed its initial public offering in February 2020 and has since advanced its platform through strategic collaborations and internal research programs. Under the leadership of Chief Executive Officer Michelle Dipp, Adicet continues to expand its cell therapy capabilities and to position its allogeneic γδ T cell technology as a potential new standard for scalable, off‐the‐shelf immunotherapies.